top of page

ASX: 1AD - AdAlta

Updated: Jul 25, 2023

AdAlta: A big development for fibrosis sufferers… and it could be lucrative too

AdAlta Managing Director Tim Oldham on 2GB & 3AW Bulls N' Bears Report

Listen to ASX-listed AdAlta Managing Director Tim Oldham talk to Matt Birney on the Bulls N’ Bears Report about AdAlta’s extraordinary new drug that just might be a game changer for fibrosis sufferers.


AdAlta is a clinical-stage drug developer based in Melbourne. The company is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis and other human fibrotic diseases for which there is a high unmet medical need. AdAlta is also entering collaborative partnerships to advance the development of its i-body platform.


Matt Birney - Welcome to Bulls N' Bears brought to you today by clinical stage drug developer AdAlta.

Matt Birney - ASX code: 1AD

Matt Birney - I'm Matt Birney and I'm joined now by the Managing Director of AdAlta, Tim Oldham.

Matt Birney - Hi Tim.

Tim Oldham - Hi Matt.

Matt Birney - Okay Tim, AdAlta is developing a new drug platform technology known as i-body that I understand focuses on cancer and also fibrotic diseases such Idiopathic Pulmonary Fibrosis.

Matt Birney - You recently tabled some data about the effectiveness of your AD-214 drug against fibrotic diseases, and we’ll get into shortly, but firstly, what exactly is a fibrotic disease, and how many people suffer from it?

Tim Oldham - Fibrosis is scarring of an internal organ and we know that when we scar that reduces the ability for an organ to function properly and that ultimately leads to health impairment and ultimately death.

Tim Oldham - In the case of Idiopathic Pulmonary Fibrosis, most patients die within four years of diagnosis. There are about half a million people living with Idiopathic Pulmonary Fibrosis or lung fibrosis around the world.

Matt Birney - How is fibrosis treated now and how are you doing it differently with your AD-214 drug In layman's terms preferably.

Tim Oldham - Standard of care today involves one of two drugs. They don't work particularly well and they have some pretty severe side effects that actually prevent many patients tolerating them for more than about a year.

Tim Oldham - Despite that, they're the best we have and that's, we spend about 4.3 billion dollars a year on those two products. We're trying to address a different mode of disease action, different pathway in fibrosis in order to achieve a better outcome.

Matt Birney - Okay so you recently did a lab study on your AD-214 drug what were you trying to achieve with that study and what did you learn?

Tim Oldham - What we wanted to know was that we could dose AD-214 at a clinically viable frequency, so we don't want to be giving an IV infusion more than about every two weeks.

Tim Oldham - The new data using a model fibrosis system was able to demonstrate that yes indeed we can deliver  an effective dose of AD-214 when dosing only every two weeks. That's fantastic news for us, our potential patient, our phase two trials and also for our potential partners.

Matt Birney - Very quickly, how do you know it works?

Tim Oldham - We have multiple animal studies of fibrotic diseases that we've used to treat with AD-214, that have demonstrated a positive response.

Matt Birney - Tim Oldham from AdAlta.

Matt Birney - Thanks for joining me on Bulls N' Bears and remember we're only here to give you information, not advice, which you should of course seek independently.

Matt Birney - I'm Matt Birney and this is Bulls N' Bears

Outro - For more public company interviews go to the money page on the 6PR, 2GB, 3AW and 4BC websites and click the public companies tab


Recent Posts

See All


bottom of page